Pei K Yu

6391582, May 21, 2002

Dec 9, 1998

09/208827

Ying Luo - Los Altos CA
Pei Wen Yu - Burlingame CA
James Lorens - Portola Valley CA

Rigel Pharmaceuticlas, Inc. - So. San Francisco CA

C12P 2102

435 691, 435466, 435477, 435483

The invention provides shuttle vectors, and methods of using shuttle vectors, capable of expression in, at least, a mammalian cell. Furthermore, the shuttle vectors are capable of replication in at least yeast, and optionally, bacterial cells. Also provided is a method wherein yeast are transformed with a shuttle vector as provided herein. Heterologous nucleic acids flanked by 5â and 3â ends identical to a homologous recombination site within the shuttle vector are introduced to the transformed yeast and allowed to homologously recombine with the shuttle vector such that they are inserted into the vector by the yeast organism. The shuttle vector is then recovered and transferred to a mammalian cell for expression.

6645766, Nov 11, 2003

Jan 7, 2002

10/043074

Ying Luo - Los Altos CA
Pei Wen Yu - Burlingame CA
James Lorens - Portola Valley CA

Rigel Pharmaceuticals, Inc. - San Francisco CA

C12N 1564

435466, 435477, 435483, 4353201, 43525421

The invention provides shuttle vectors, and methods of using shuttle vectors, capable of expression in, at least, a mammalian cell. Furthermore, the shuttle vectors are capable of replication in at least yeast, and optionally, bacterial cells. Also provided is a method wherein yeast are transformed with a shuttle vector as provided herein. Heterologous nucleic acids flanked by 5â and 3â ends identical to a homologous recombination site within the shuttle vector are introduced to the transformed yeast and allowed to homologously recombine with the shuttle vector such that they are inserted into the vector by the yeast organism. The shuttle vector is then recovered and transferred to a mammalian cell for expression.

7223850, May 29, 2007

Aug 6, 1999

09/762491

Ying Luo - Los Altos CA, US
Betty Huang - San Leandro CA, US
Mary Shen - Newark CA, US
Pei Wen Yu - Cupertino CA, US

Rigel Pharmaceuticals, Inc. - South San Francisco CA

C12N 15/11
C07K 14/00

536 231, 4353201, 435 4, 435 6, 530350

The present invention is directed to novel apoptosis polypeptides such as the Apop1, and Apop3 proteins and related molecules which are involved in modulating apoptosis and to nucleic acid molecules encoding those polypeptides. Also provided here are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which modulate the biological activity of Apop1, Apop2, and Apop3, and the use of such compositions in diagnosis and treatment of disease.

7488805, Feb 10, 2009

Apr 24, 2007

11/739267

Ying Luo - Los Altos CA, US
Betty Huang - San Leandro CA, US
Mary Shen - Newark CA, US
Pei Wen Yu - Cupertino CA, US

Rigel Pharmaceuticals, Inc. - South San Francisco CA

C07K 16/00

53038815, 5303871, 5303879

The present invention is directed to novel apoptosis polypeptides such as the Apop1, Apop2, and Apop3 proteins and related molecules which are involved in modulating apoptosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are method for identifying novel compositions which modulate the biological activity of Apop1, Apop2, and Apop3, and the use of such compositions in diagnosis and treatment of disease.

20060228761, Oct 12, 2006

Dec 6, 2005

11/295841

Ying Luo - Shanghai, CN
Pei Yu - Cupertino CA, US
Mary Shen - Newark CA, US
Betty Huang - San Leandro CA, US

Rigel Pharmaceuticals, Inc. - South San Francisco CA

G01N 33/574
C07H 21/04
C12P 21/06
C40B 30/06
C07K 14/82
C07K 16/30

435007230, 435069100, 435320100, 435325000, 530350000, 530388220, 536023500

The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.

62809377, Aug 28, 2001

Aug 14, 1998

9/133944

Ying Luo - Los Altos CA
Pei Wen Yu - Burlingame CA
James Lorens - Portola Valley CA

Rigel Pharmaceuticals, Inc. - South San Francisco CA

C12Q 168

435 6

The invention provides shuttle vectors, and methods of using shuttle vectors, capable of expression in, at least, a mammalian cell. Furthermore, the shuttle vectors are capable of replication in at least yeast, and optionally, bacterial cells. Also provided is a method wherein yeast are transformed with a shuttle vector as provided herein. Heterologous nucleic acids flanked by 5' and 3' ends identical to a homologous recombination site within the shuttle vector are introduced to the transformed yeast and allowed to homologously recombine with the shuttle vector such that they are inserted into the vector by the yeast organism. The shuttle vector is then recovered and transferred to a mammalian cell for expression.

20200211052, Jul 2, 2020

Dec 31, 2018

16/237581

- Redmond WA, US
Christopher D. Erbach - Palo Alto CA, US
Pei Qun Yu - Sunnyvale CA, US
Nirav Nalinbhai Shingala - Santa Clara CA, US
Alexandros Ntoulas - Sunnyvale CA, US
Rohan Rajiv - Santa Clara CA, US

G06Q 30/02
G06N 20/00

Techniques for optimizing content item delivery for installations or activations of a mobile application are provided. In one technique, a machine-learned model is trained based on multiple training instances that individually indicate whether an entity performed a particular action relative to a mobile application. In response to receiving a content item request from a third-party content delivery exchange, it is determined whether a client device that initiated the content item request has activated a particular application. In response to determining that the client device has not activated the particular application, multiple feature values of the content item request are identified. Based on inputting the feature values into the model, a score is generated that indicates a likelihood that an entity of the client device will perform the particular action relative to the particular application. Based on the score, a content item is transmitted over a network to the client device.